Menu
Search
|

Menu

Close
X

Shire PLC SHPG.OQ (NASDAQ Stock Exchange Global Select Market)

134.06 USD
+0.00 (+0.00%)
As of Feb 16
chart
Previous Close 134.06
Open --
Volume 14,921
3m Avg Volume 427,056
Today’s High --
Today’s Low --
52 Week High 192.15
52 Week Low 123.73
Shares Outstanding (mil) 303.26
Market Capitalization (mil) 39,731.55
Forward P/E 6.12
Dividend (Yield %) 0.89 ( 0.78 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 15 analysts

KEY STATS

Revenue (mm, USD)
FY17
15,161
FY16
11,397
FY15
6,417
EPS (USD)
FY17
7.297
FY16
0.920
FY15
2.255
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
6.12
35.76
Price to Sales (TTM)
vs sector
2.62
8.59
Price to Book (MRQ)
vs sector
1.13
5.23
Price to Cash Flow (TTM)
vs sector
4.47
26.13
Total Debt to Equity (MRQ)
vs sector
54.02
15.32
LT Debt to Equity (MRQ)
vs sector
46.31
11.95
Return on Investment (TTM)
vs sector
11.13
13.59
Return on Equity (TTM)
vs sector
20.37
15.20

EXECUTIVE LEADERSHIP

Susan Kilsby
Independent Non-Executive Chairman of the Board, Since 2014
Salary: --
Bonus: --
Flemming Ornskov
Chief Executive Officer, Executive Director, Since 2013
Salary: $1,688,000.00
Bonus: --
John Miller
Interim Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Joanne Cordeiro
Chief Human Resource Officer, Since 2017
Salary: --
Bonus: --
Andreas Busch
Executive Vice President - Head of Research and Development, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Miesian Plaza
50-58 Baggot Street Lower, Block
DUBLIN     D02 HW68

Phone: +3531.6096000

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

SPONSORED STORIES